Unum Therapeutics Inc. (NASDAQ:UMRX) Plunges in Premarket

Unum Therapeutics Inc. (NASDAQ:UMRX) continued to plummet Wednesday, a day after the company said the Food and Drug Administration had suspended a trial of one of its cancer drugs after a patient experienced serious side effects. The biotech company, which went public last year, remains in the clinical stage, which means it has no drugs on the market.

The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the UMRX is 39.76%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. The Institutional ownership for the UMRX is 47.80%.

Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that UMRX. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public.

Institutional transactions is the amount of a Unum Therapeutics Inc. (NASDAQ:UMRX)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the UMRX is -0.33%.

[finviz ticker=umrx]

A Healthcare sector firm, Unum Therapeutics Inc. (NASDAQ:UMRX) stock tanked -9.13% on Tuesday and when day-trade ended the stock finally concluded at $2.19 and number of shares that changed hands during the day are 134851. The number of shares UMRX stock currently held by all its shareholders are 25.19 and floated shares, the number of shares are available for trading in an open market on last trading day are 18.16. The average volume of shares for 3 months is 150.08 and UMRX stock value has moved between $2.11 – 18.25 in last one year.

The Unum Therapeutics Inc. (NASDAQ:UMRX)’s latest earnings date is 8/12/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The stock has gained -50.23% in 2019 to date.

Unum Therapeutics Inc. (NASDAQ:UMRX)’s monthly stock performance is -37.07%, the quarterly performance is -48.83%, the half year performance is calculated as -50.23%. The yearly performance of UMRX is -84.74%.

The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Unum Therapeutics Inc. (NASDAQ:UMRX) weekly volatility is measured as 19.01% and monthly volatility measured as 13.12%.

Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. UMRX return on assets is -43.30%, the return on equity (ROE) of the Unum Therapeutics Inc. (NASDAQ:UMRX) is -62.30%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and UMRX return on investment is -59.80%.

The price to sales ratio is 5.20, and price to book ratio is 1.34, price to cash per share ration is 0.82.

Analysts mean target price for Unum Therapeutics Inc. (NASDAQ:UMRX) is $16.50 while analysts mean recommendation is 2.00. The current share price indicates that stock is -87.60% away from its one year high and is moving 4.29% ahead of its 52-week low. UMRX’s distance from 20 day simple moving average is -18.33% and distance from 50-Day simple moving average is -29.35%.

See also  Morgan Stanley (NYSE:MS) states now time to purchase emerging-market currencies

Leave a Reply